TNFRSF8 and neoplasm: [137] demonstrated that the nanobody‐based CD30‐CD5‐CAR‐T cells exhibited superior anti‐tumor effects against T cell lymphoma (TCL) in both in vivo and in vitro experiments, suggesting that nanobody‐based CAR‐T cells could dramatically improve their anti‐tumor efficiency compared with conventional scFv‐derived CAR‐T cells.